Delgado D, Dabbous F, Shivappa N, Mazhar F, Wittbrodt E, Shridharmurthy D et al (2025) Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review. Orphanet J Rare Dis 20(1):29. https://doi.org/10.1186/s13023-025-03547-0

Article  PubMed  PubMed Central  Google Scholar 

Kittleson MM, Ambardekar AV, Cheng RK, Griffin JM, Maurer MS, Nativi-Nicolau J et al (2025) Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance. J Am Coll Cardiol. 87(5):549–565 https://doi.org/10.1016/j.jacc.2025.09.004

Article  PubMed  PubMed Central  Google Scholar 

Ruberg FL, Teruya S, Helmke S, Smiley DA, Fine D, Kurian D et al (2025) Transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure. JAMA Cardiol 10(10):1035–1043. https://doi.org/10.1001/jamacardio.2025.2948

Article  PubMed  PubMed Central  Google Scholar 

Ruberg FL, Maurer MS (2024) Cardiac amyloidosis due to transthyretin protein: a review. JAMA 331(9):778–791. https://doi.org/10.1001/jama.2024.0442

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antonopoulos AS, Tsampras T, Lazaros G, Tsioufis K, Vlachopoulos C (2025) A phenomap of TTR amyloidosis to aid diagnostic screening. ESC Heart Fail 12(2):1113–1118. https://doi.org/10.1002/ehf2.15143

Article  PubMed  Google Scholar 

Dispenzieri A, Coelho T, Conceição I, Waddington-Cruz M, Wixner J, Kristen AV et al (2022) Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet J Rare Dis 17(1):236. https://doi.org/10.1186/s13023-022-02359-w

Article  PubMed  PubMed Central  Google Scholar 

Adams D, Ando Y, Beirao JM, Coelho T, Gertz MA, Gillmore JD et al (2021) Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol 268(6):2109–2122. https://doi.org/10.1007/s00415-019-09688-0

Article  PubMed  Google Scholar 

Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y (2018) Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis 13(1):6. https://doi.org/10.1186/s13023-017-0726-x

Article  PubMed  PubMed Central  Google Scholar 

Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B et al (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 68(2):161–172. https://doi.org/10.1016/j.jacc.2016.03.596

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhatt K, Delgado DH, Khella S, Bumma N, Karam C, Keller A et al (2024) Hereditary transthyretin amyloidosis in patients referred to a genetic testing program. J Am Heart Assoc 13(23):e033770. https://doi.org/10.1161/jaha.123.033770

Article  CAS  PubMed  PubMed Central  Google Scholar 

Madhani A, Sabogal N, Massillon D, Paul LD, Rodriguez C, Fine D et al (2023) Clinical penetrance of the transthyretin V122I variant in older black patients with heart failure: the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. J Am Heart Assoc 12(15):e028973. https://doi.org/10.1161/jaha.122.028973

Article  CAS  PubMed  PubMed Central  Google Scholar 

Selvaraj S, Claggett B, Shah SH, Mentz RJ, Khouri MG, Manichaikul AW et al (2024) Cardiovascular burden of the V142I transthyretin variant. JAMA 331(21):1824–1833. https://doi.org/10.1001/jama.2024.4467

Article  CAS  PubMed  PubMed Central  Google Scholar 

Conceição I, Damy T, Romero M, Galán L, Attarian S, Luigetti M et al (2019) Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid 26(1):3–9. https://doi.org/10.1080/13506129.2018.1556156

Article  CAS  PubMed  Google Scholar 

Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO et al (2023)ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol 81(11):1076–1126. https://doi.org/10.1016/j.jacc.2022.11.022

Article  PubMed  Google Scholar 

Akinboboye O, Shah K, Warner AL, Damy T, Taylor HA, Gollob J et al (2020) DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis. Amyloid 27(4):223–230. https://doi.org/10.1080/13506129.2020.1764928

Article  CAS  PubMed  Google Scholar 

Damrauer SM, Chaudhary K, Cho JH, Liang LW, Argulian E, Chan L et al (2019) Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic/Latino ancestry. JAMA 322(22):2191–2202. https://doi.org/10.1001/jama.2019.17935

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacoby E, Quan D, Todd E, Shortt J, Smith H, Rafaels N et al (2025) Prevalence of pathogenic transthyretin gene variants in the Rocky Mountain region. Muscle Nerve 71(2):252–256. https://doi.org/10.1002/mus.28301

Article  PubMed  Google Scholar 

Desai U, Ilieva HS, Eyer JE, Peltier AC (2025) Peripheral nervous system involvement of hereditary transthyretin amyloidosis in the United States: a multi-center perspective. Muscle Nerve 72(2):286–293. https://doi.org/10.1002/mus.28414

Article  PubMed  Google Scholar 

Ioannou A, Nitsche C, Porcari A, Patel RK, Razvi Y, Rauf MU et al (2024) Multiorgan dysfunction and associated prognosis in transthyretin cardiac amyloidosis. J Am Heart Assoc 13(4):e033094. https://doi.org/10.1161/jaha.123.033094

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grodin JL, Gupta A, Rison I Jr., Kozlitina J, Saelices-Gomez L, Girotra S et al (2025) Risk for heart failure and atrial fibrillation across the lifespan for carriers of the amyloidogenic p.V142I TTR variant. Circ Genom Precis Med 18(4):e004911. https://doi.org/10.1161/circgen.124.004911

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coniglio AC, Segar MW, Loungani RS, Savla JJ, Grodin JL, Fox ER et al (2022) Transthyretin V142I genetic variant and cardiac remodeling, injury, and heart failure risk in black adults. JACC Heart Fail 10(2):129–138. https://doi.org/10.1016/j.jchf.2021.09.006

Article  CAS  PubMed  Google Scholar 

Parcha V, Malla G, Irvin MR, Armstrong ND, Judd SE, Lange LA et al (2022) Association of transthyretin Val122Ile variant with incident heart failure among Black individuals. JAMA 327(14):1368–1378. https://doi.org/10.1001/jama.2022.2896

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rao VN, Claggett BL, Khouri MG, Shah AM, Solomon SD, Selvaraj S (2025) Late-life echocardiographic effects of the amyloidogenic p.V142I transthyretin variant. Circ Heart Fail 18(7):e013212. https://doi.org/10.1161/circheartfailure.125.013212

Article  CAS  PubMed  PubMed Central  Google Scholar 

Selvaraj S, Claggett B, Minamisawa M, Windham BG, Chen LY, Inciardi RM et al (2021) Atrial fibrillation and ischemic stroke with the amyloidogenic V122I transthyretin variant among Black Americans. J Am Coll Cardiol 78(1):89–91. https://doi.org/10.1016/j.jacc.2021.04.042

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sideris K, Nelson TJ, Brinker L, Gao A, Tcheandjieu C, Kyriakopoulos CP et al (2026) Systemic manifestations and mortality risk in transthyretin V142I variant carriers: a million veteran program analysis. JACC Cardio Oncology 8(1):31–44. https://doi.org/10.1016/j.jaccao.2025.12.006

Article  Google Scholar 

Ioannou A, Patel RK, Razvi Y, Porcari A, Sinagra G, Venneri L et al (2022) Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation 146(22):1657–1670. https://doi.org/10.1161/circulationaha.122.060852

Article  CAS  PubMed  PubMed Central